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OBJECTIVE—Epidemiological and family studies have demon-
strated that susceptibility genes play an important role in the
etiology of diabetic nephropathy, deﬁned as persistent protein-
uria or end-stage renal disease (ESRD) in type 1 diabetes.
RESEARCH DESIGN AND METHODS—To efﬁciently search
for genomic regions harboring diabetic nephropathy genes, we
conducted a scan using 5,382 informative single nucleotide
polymorphisms on 100 sibpairs concordant for type 1 diabetes
but discordant for diabetic nephropathy. In addition to being
powerful for detecting linkage to diabetic nephropathy, this
design allows linkage analysis on type 1 diabetes via traditional
affected sibpair (ASP) analysis. In weighing the evidence for
linkage, we considered maximum logarithm of odds score (max-
imum likelihood score [MLS]) values and corresponding allelic
sharing patterns, calculated and viewed graphically using the
software package SPLAT.
RESULTS—Our primary ﬁnding for diabetic nephropathy,
broadly deﬁned, is on chromosome 19q (MLS  3.1), and a
secondary peak exists on chromosome 2q (MLS  2.1). Stratiﬁ-
cation of discordant sibpairs based on whether disease had
progressed to ESRD suggested four tertiary peaks on chromo-
some 1q (ESRD only), chromosome 20p (proteinuria only), and
chromosome 3q (two loci 58 cm apart, one for ESRD only and
another for proteinuria only). Additionally, analysis of 130 ASPs
for type 1 diabetes conﬁrmed the linkage to the HLA region on
chromosome 6p (MLS  9.2) and IDDM15 on chromosome 6q
(MLS  3.1).
CONCLUSIONS—This study identiﬁed several novel loci as
candidates for diabetic nephropathy, none of which appear to be
the sole genetic determinant of diabetic nephropathy in type 1
diabetes. In addition, this study conﬁrms two previously reported
type 1 diabetes loci. Diabetes 57:2519–2526, 2008
D
iabetic nephropathy is the major complication of
type 1 diabetes. Clinically, diabetic nephropathy
is manifested as persistent proteinuria that fre-
quently progresses to end-stage renal disease
(ESRD) (1). While hyperglycemia plays a major role in
diabetic nephropathy (1), genetic predisposition has become
apparent. Familial aggregation of diabetic nephropathy has
been observed in all family studies with multiple type 1
diabetic siblings (2–6). The most comprehensive study,
conducted at the Joslin Clinic (4), demonstrated that in
comparison with a lifetime diabetic nephropathy risk of
35% among unrelated patients with type 1 diabetes, the
risk to a second diabetic sibling increases to 72% or
decreases to 25%, depending on whether the ﬁrst dia-
betic sibling had diabetic nephropathy. Since familial
clustering of glycemic control could not account for this
large disparity, a major gene effect was proposed as a
plausible explanation (4). To map such a gene, we
showed that discordant sibpairs (DSPs) for diabetic
nephropathy would be four times as efﬁcient as affected
sibpairs (ASPs) (7).
Previously, we applied the DSP strategy to a collection
of 66 DSPs to test for linkage with genes of the renin-
angiotensin system (8). Manual genotyping of microsatel-
lites did not identify any evidence for linkage with AGT
(chromosome 1q) and ACE (chromosome 17q); however,
we obtained suggestive evidence for linkage with the
region on chromosome 3q containing ATR1 (8). Subse-
quent sequencing of this gene and association studies,
however, excluded this gene (8). This report features a
larger sample size (100 DSPs from 83 families) and a more
stringent deﬁnition of diabetic nephropathy.
RESEARCH DESIGN AND METHODS
We identiﬁed patients with type 1 diabetes and diabetic nephropathy attending
the Joslin Clinic between 1991 and 2003. Of 900 of such patients, 714 (95%
Caucasians) were enrolled into the Joslin Study on Genetics of Diabetic Nephrop-
athy. Initially, we identiﬁed 125 families having a diabetic nephropathy proband
with one or more living siblings with 10 years of type 1 diabetes. After consent,
each participant was examined by a trained recruiter. For siblings not attending
the Joslin Clinic, we obtained medical record information from their primary
physicians. The committee on human subjects of the Joslin Diabetes Center
approved the protocol and informed consent procedures.
Diagnosis of type 1 diabetes and diabetic nephropathy. Type 1 diabetes was
assumed if hyperglycemia was diagnosed before age 35 years and its control
required insulin treatment within 1 year of diagnosis. The diabetic nephrop-
athy status of each patient was determined on the basis of questionnaires,
From the
1Research Division, Joslin Diabetes Center, Boston, Massachusetts;
the
2Department of Medicine, Harvard Medical School, Boston, Massachu-
setts; the
3Department of Internal Medicine, Nephrology and Dialysis,
Medical University of Lodz, Lodz, Poland; the
4Department of Endocrinol-
ogy, Universidade Federal do Rio Grande Do Sul, Porto Alegre, Brazil; the
5Department of Internal Medicine, Shiga University of Medical Science,
Otsu, Japan; and the
6Division of Nephrology, Department of Internal
Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Correspondingauthor:AndrzejS.Krolewski,andrzej.krolewski@joslin.harvard.
edu.
Received 6 August 2007 and accepted 12 June 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 16 June
2008. DOI: 10.2337/db07-1086.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
DIABETES, VOL. 57, SEPTEMBER 2008 2519medical records, and measurements of the urinary albumin-to-creatinine ratio
using a previously described method (9). Patients were classiﬁed as not having
diabetic nephropathy if they had 10 years of diabetes and a urinary
albumin-to-creatinine ratio 20 mg/g in two of three consecutive urine
specimens. Patients were considered case subjects if they had persistent
proteinuria, ESRD, or renal transplant. Persistent proteinuria was deﬁned as
two of three successive positive urinalyses determined either by a urinary
albumin-to-creatinine ratio 250 mg/g (men) or 355 mg/g (women) or by a
Multistix reagent strip (2; Bayer, Elkhart, IN).
Examined families. Of 125 initial families, 42 were excluded because all
siblings had either subclinical (microalbuminuria) or clinical (proteinuria or
ESRD) evidence of diabetic nephropathy. The remaining 83 examined families
each contained at least one type 1 diabetic sibling with diabetic nephropathy
and one type 1 diabetic sibling without diabetic nephropathy. The distribution
of diabetic siblings per family and the number of examined parents is shown
in Table 1. Among these 83 families, we examined 80 parents, 96 siblings with
type 1 diabetes but without diabetic nephropathy, 43 diabetic siblings with
persistent proteinuria, and 44 diabetic siblings with ESRD. There were a total
of 130 sibpairs concordant for type 1 diabetes and 100 sibpairs discordant for
diabetic nephropathy.
Clinical characteristics of siblings. Clinical characteristics were obtained
during the enrollment examination. This information was supplemented with
data abstracted from the Joslin Clinic medical records or obtained from
primary care physicians.
DNA extraction and genotyping. DNA was extracted using a standard
phenol-chloroform protocol. Samples were genotyped by Illumina Genotyping
Services (San Diego, CA) with Illumina’s high-throughput BeadArray Platform
utilizing single nucleotide polymorphisms (SNPs) from their Linkage 4b
Mapping Panel, which consists of 6,008 validated SNPs with an average
heterozygosity 45% (in Caucasians) and an average interpolated genetic map
distance of 0.62 cM. This panel was determined by simulation to allow for the
extraction of most inheritance information.
Data management and cleaning. Data were managed in SAS. The original
dataset consisted of 5,984 SNPs. Five samples were genotyped as quality-
control duplicates. Of nearly 30,000 replicated quality-control genotypes, not
a single mismatched allele call was observed. The sample with the lowest
quality genotyping had a 4.8% no-call rate and 86.8% GenCall 0.7; thus we
rejected no samples based on genotyping quality. Using the Wiggington
algorithm, we found only three SNPs that violated Hardy-Weinberg. None of
these had a material impact on our results. All analyzed pairs were conﬁrmed
as full sibs with Prest (10).
Among the original 5,984 SNPs, 602 were removed before analysis: 343
localized to sex chromosomes, 20 were monomorphic, and 239 were not of
sufﬁcient quality (98% of genotypes with a GenCall score 0.7). Thus, our
autosomal genome scan utilized 5,382 high-quality, informative SNPs (mean
information content of 84.9%). Mendelian errors were evaluated with Ped-
Check (11). Interestingly, nine of these occurred in a single sample at the
chromosome 18p telomere. Upon further investigation, this sample was found
to be homozygous across each of the ﬁrst 37 SNPs, thus implying the existence
of a large chromosomal deletion. Genotypes for this and another such region
were removed, as were the remaining observed Mendelian errors. Finally, we
used Merlin (12) to remove less obvious genotyping errors. In total, we
removed 442 genotype errors identiﬁed by PedCheck and 334 genotypes
ﬂagged by Merlin.
Genetic analysis. Since linkage disequilibrium can introduce bias (13), we
used the linkage disequilibrium modeling capabilities of Merlin (14) in
calculating IBD statistics. Simulation studies have shown that maximum
likelihood score (MLS) inﬂation is negligible for r
2  0.16 (15), so we used this
threshold. Merlin identiﬁed all clusters for which r
2 exceeded 0.16 and ran the
expectation-maximization algorithm to calculate haplotype frequencies, thus
reducing bias due to linkage disequilibrium. Two clusters with obligate
recombinants were removed before analysis.
The resulting IBD ﬁles were combined and converted to Genehunter
format then, in conjunction with a phenotype ﬁle, analyzed with SPLAT (16).
SPLAT used the phenotype ﬁle to deﬁne DSPs and then implemented the
expectation-maximization algorithm to calculate maximum-likelihood esti-
mates of sharing and corresponding MLS values for each chromosomal
position. For DSPs, diminished sharing (mean sharing 0.49 and z2  0.2) was
required for declaring linkage (17). Unless otherwise indicated, the MLS
values reﬂect unconstrained maximization and should be compared with
reference distribution with two degrees of freedom. Contour plots of peak
MLS values together with various constraint regions are available in an online
appendix (available at http://dx.doi.org/10.2337/db07-1086). For comparison to
Lander-Kruglyak criteria (17), we report the largest MLS value falling in the
ASP/DSP triangle. For both ASPs and DSPs, triangle-constrained values 4.0
are considered signiﬁcant and 2.6 are considered suggestive (17,18). Calcu-
lations underlying these thresholds assume all inheritance information is
extracted, so there is no need to adjust further for the large number of SNPs
genotyped.
Genetic maps. All genetic positions refer to the deCODE genetic map, and
ﬁndings from previous studies have been converted to this scale.
RESULTS
Characteristics of examined families. Clinical charac-
teristics are shown in Table 2. Siblings with diabetic
nephropathy, particularly those with ESRD, had shorter
diabetes duration, were younger, and the majority had
retinopathy requiring laser treatment. About one-third of
siblings without diabetic nephropathy had had severe
diabetic retinopathy requiring laser treatment. All siblings
were treated with insulin and had similar A1C levels at
enrollment. In short, all siblings had typical type 1 diabetes
and the different diabetic nephropathy status of these
siblings could not be accounted for by differences in
diabetes duration. Our families comprise 130 ASPs for
type 1 diabetes and 100 DSPs for diabetic nephropathy.
Linkage scan for type 1 diabetes loci. The 130 ASPs for
type 1 diabetes were used to search for chromosomal
regions with increased allele sharing (i.e., 25% sharing
both chromosomes and mean allele sharing 50%). We
present these results for two important reasons. First, the
highly signiﬁcant peak (MLS  9.6 at 52 cM) location in the
HLA region of chromosome 6p (Fig. 1) provides validation
that our patient population is comprised of type 1 diabetic
patients. Second, these results provide additional informa-
tion throughout the genome to those studying the genetics
of type 1 diabetes. Excluding HLA, the largest MLS occurs
at a secondary peak on chromosome 6q (MLS  3.1 at
141–143 cM) (Fig. 1). Here, the type 1 diabetic ASPs have
60% mean allele sharing and 42.6% share both alleles.
The only other notable result from the ASP scan occurs on
chromosome 5. However, the proportion of ASPs sharing
both alleles at this location (19%) is uncharacteristically
low for a true linkage result.
TABLE 1
Characteristics of families with type 1 diabetes used in the linkage study
Number of examined diabetic siblings per family
Number of examined parents per family
Two One None Total families
Number of families
Two (control and proteinuria) 11 11 13 35
Two (control and ESRD) 12 12 8 32
Three or more (control and proteinuria or ESRD) 0 11 5 16*
Total families 23 34 26 83†
*Fifteen families with three siblings and one family with four siblings. †In these families, there were 130 sibpairs concordant for diabetes and
100 sibpairs discordant for diabetic nephropathy.
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loci. In contrast to the analysis carried out in 130 ASPs for
type 1 diabetes, the 100 DSPs for diabetic nephropathy
were analyzed to search for chromosomal regions with
diminished sharing. This implies that 25% of the DSPs
will share neither of their two chromosomes in the vicinity
of the gene, leading to mean allele sharing 50%.
Fifteen chromosomes show no evidence of linkage (see
online appendix). Figure 2 shows the remaining chromo-
somes and also chromosome 3, since we have previously
reported linkage to this chromosome (8). The peak on
chromosome 19 is the strongest (MLS  3.1 at 107.2 cM).
Three peaks have MLS 2: chromosome 5 (MLS  2.7 at
118 cM), chromosome 10 (MLS  2.5 at 142 cM), and
chromosome 2 (MLS  2.1 at 125 cM). Three others have
MLS 1: chromosome 17 (MLS  1.9 at 28 cM), chromo-
some 20 (MLS  1.8 at 42 cM), and chromosome 1 (MLS 
1.6 at 266 cM). Three regions in Fig. 2 have a sharing
pattern not reﬂective of linkage, characterized by an
increased proportion of sharing one allele (67, 65, and 65%
on chromosomes 5, 10, and 17, respectively) but a de-
creased proportion sharing neither allele (20, 25, and 21%
on chromosomes 5, 10, and 17, respectively).
Progression from proteinuria to ESRD occurred in ex-
actly half of the 100 DSPs, providing a natural partition of
families for subanalysis (Table 3). The highest peak in the
combined analysis (MLS  3.1 on chromosome 19) shows
strong consistency in both MLS values and sharing pat-
terns in the two phenotypic subsets (MLS values of 1.9
[ESRD] and 1.8 [proteinuria] with zero allele sharing of 43
and 42%, respectively). The region on chromosome 2
shows similar consistency (MLS values of 1.3 [ESRD] and
1.4 [proteinuria] with zero allele sharing of 40 and 36%,
respectively). In contrast, chromosome 20 results arise
solely from the 50 DSPs with proteinuria (MLS  2.8) and
chromosome 1 results arise solely from the 50 DSPs with
ESRD (MLS  1.8). An additional twist emerges for
chromosome 3. There, the rather modest peak in the set of
all 100 DSPs (MLS  0.6) partitions into two distinct
peaks, one at 96 cM for the 50 DSPs with proteinuria
(MLS  1.5) and one at 154 cM for the 50 DSPs with ESRD
(MLS  1.1). Finally, of three chromosomes with sharing
patterns not consistent with linkage in the overall dataset,
the chromosome 10q region was consistent with linkage in
the set of 50 DSPs with proteinuria (MLS  1.7).
Reﬁnement of results based on sharing patterns.
Because siblings can share zero, one, or two alleles at a
given chromosomal location, describing the sharing pat-
TABLE 2
Clinical characteristics of examined diabetic siblings according to renal status
Characteristics
Control subjects with
normoalbuminuria
Case subjects with
proteinuria
Case
subjects
with
ESRD
n 96 42 44*
Men (%) 42 57 48
Age at diagnosis of diabetes (years) 15  10 12  81 2  8
Duration of diabetes (years)† 28  10‡ 28  62 5  9§
Age (years)† 43  94 0  83 7  9§
Total insulin dose (units)† 48  24 50  24 38  17
A1C (%)† 8.1  1.7 8.3  1.2 8.1  2.2
Retinopathy requiring laser treatment (%)† 30 62 88
Serum creatinine (mg/dl)† 0.9  0.2 1.6  0.8 NA
*This group consists of 14 patients with new-onset ESRD, 2 patients on hemodialysis, and 28 patients with kidney transplant. †At the time
of the enrollment into the study. In control subjects 10% were treated with antihypertensive drugs (including ACE inhibitors). ‡In control
subjects, 33, 35, and 32% had duration of diabetes for 10–19 years, 20–29 years, and 30–49 years, respectively. §Value at the time of initiation
of renal replacement therapy.
FIG. 1. Chromosome 6 linkage results for 130 sibpairs concordant for type 1 diabetes. The computations and the plots were obtained using SPLAT
(16).
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alleles and the proportion sharing one allele. The remain-
ing siblings share two alleles. Under the null hypothesis,
siblings share zero, one, or two alleles with frequencies of
25, 50, and 25%, respectively.
The two free parameters can be visualized on a two-
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FIG. 2. Linkage results for 100 sibpairs concordant for type 1 diabetes and discordant for nephropathy. Siblings considered unaffected had
normoalbuminuria despite a minimum of 10 years duration of diabetes, while affected siblings had proteinuria or ESRD. The computations and
the plots were obtained using SPLAT (16).
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2522 DIABETES, VOL. 57, SEPTEMBER 2008dimensional graph with the constraint that the sum of the
two parameters is one or more. However, not all patterns are
consistent with those likely to occur in the vicinity of a
susceptibility gene. Holmans (19) systematically character-
ized the patterns consistent with linkage in ASPs (Holmans’
“ASP Triangle,” see Fig. 3). We derived the analogous trian-
gular region for DSPs (18), also shown in Fig. 3. The only
point of overlap of the two triangles is the null hypothesis.
Otherwise, the entire ASP triangle falls in the region of
increased mean sharing and the entire DSP triangle falls in
the region of decreased mean sharing.
Figure 3 shows that the two ASP results on chromosome
6 are in the ASP triangle, but the ASP result on chromo-
some 5 is far from it, reinforcing our observation that the
sharing pattern on chromosome 5 is not typical of linkage.
For the 100 DSPs, the results for chromosomes 19, 2, 20,
and 3 are within the DSP triangle, while the chromosome
1 result is not. We also get a visual sense of the clustering
of the chromosome 5, 10, and 17 results, which are outside
of the DSP triangle and dissimilar to the null hypothesis
primarily because of an excess of one allele sharing.
The sharing patterns in the subphenotypes of ESRD and
proteinuria, reported in Table 3, can be viewed graphically
in the online appendix. For chromosome 2, the peak for
the proteinuria group is within the DSP triangle, while the
peak for the ESRD group is nearby but just outside the
triangle. The proximity of these two peaks to each other
suggests a single linked locus, which is independent of
subphenotype, located close to the lower boundary of the
DSP triangle. That the actual sharing pattern for protein-
uria falls just below the boundary is not concerning, since
the corresponding point estimate of the location also has a
rather wide conﬁdence interval. A similar situation occurs
for chromosome 19, where the peaks for ESRD and
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overall sample. Here, the peaks for both subphenotypes
fall just below the lower boundary of the DSP triangle,
again likely due to sampling variation in a small sample.
The chromosome 3 peaks for subphenotypes are also
close to each other and just below the lower boundary of
the DSP triangle. The chromosome 1 peak in ESRD is in a
similar location to the overall peak, which is just below the
DSP triangle.
DISCUSSION
Our primary ﬁnding for linkage to diabetic nephropathy
is on chromosome 19q (triangle MLS  3.1), with a
secondary peak on chromosome 2q (triangle MLS 
2.1). The former, but not the latter, exceeds the Lander
and Kruglyak criterion of triangle MLS 2.6 (17,18) for
suggestive linkage. For reference, triangle MLS values of
3.3, 2.3, and 1.7 correspond to unadjusted P values of
0.0001, 0.001, and 0.005, respectively.
Stratiﬁcation of DSPs based on proteinuria or ESRD
suggested four tertiary peaks: linkage with ESRD on
chromosome 1q (MLS  1.8), linkage with proteinuria on
chromosome 20p (MLS  2.8), and linkage with two
separate regions on chromosome 3q, one for proteinuria
(MLS  1.5) and another, 58 cM away, for ESRD (MLS 
1.1). We also found two chromosomal regions linked with
type 1 diabetes. The most striking, not surprisingly, was on
chromosome 6p (MLS  9.2, 52 cM), conﬁrming the
well-established linkage with HLA. We also replicated
IDDM15 on chromosome 6q (MLS  3.1, 142 cM) (http://
t1dbase.org/page/Loci/display/?speciesHuman).
Two previous publications have used the DSP study design
developed by our group. The ﬁrst was a pilot study done at
Joslin Diabetes Center (8). Sixty-six DSPs from 52 families
were used to test chromosomal regions containing genes of
the renin-angiotensin system. We found no evidence for
linkage with AGT (chromosome 1q) or with ACE (chromo-
some 17q); however, we did obtain suggestive evidence
(MLS  3.1 at 157 cM) on the chromosome 3q region
containing ATR1. In the second study of 83 DSPs from 73
Finnish families with type 1 diabetes, suggestive evidence
was found on chromosome 3q (MLS  2.7 at 141 cM). The
sharing patterns leading to the linkage effect were not
presented (20).
Contrary to these studies, the strongest linkage signal in
our current study is on chromosome 19q. Our enthusiasm for
this ﬁnding stems not only from the magnitude of the linkage
statistic but also from the sharing pattern, which occurs well
within the DSP triangle. Moreover, this signal was detected in
both phenotypic subsets (ESRD and proteinuria). The 1
logarithm of odds support interval around the combined
ESRD/proteinuria DSP result encompasses 6.5 cm, within
which there are 136 genes (94 known and 42 hypothetical or
predicted) (see online appendix).
As with chromosome 19q, our secondary peak on chro-
mosome 2q (MLS  2.1) has a sharing pattern consistent
with linkage, and the peak exists in both subsets of DSPs.
The 1 logarithm of odds support interval around the
combined ESRD/proteinuria DSP result encompasses 25
cM, within which there are 206 genes (100 known and 106
hypothetical or predicted) (see online appendix).
Our remaining ﬁndings stemmed from subset analysis of
50 DSPs deﬁned by ESRD and 50 DSPs deﬁned by protein-
uria. Speciﬁcally, we found modest evidence for linkage with
ESRD on chromosome 1q (MLS  1.8). Conversely, there is
evidence for linkage with proteinuria on chromosome 20p
(MLS  2.8). The results on chromosome 3q point toward
two separate regions: one linked to proteinuria (MLS  1.5)
and another, 58 cM away, linked to ESRD (MLS  1.1). One
possible explanation is phenotypic heterogeneity, with some
locus (or loci) related to abnormalities in urinary albumin
excretion (UAE) and others related to progression to ESRD
(or differences in survival rates once ESRD occurs). Re-
cently, we demonstrated such phenotypic heterogeneity in
extended families with type 2 diabetes. In particular, we
performed a whole genome scan using variance components
analysis to study two renal phenotypes, UAE and renal
function estimated with serum cystatin C. We found strong
or suggestive evidence for linkage to UAE on chromosome
5q, 7q, and 22p (21) and independently strong or suggestive
evidence for linkage to renal function on chromosome 2q, 7p,
10q, and 18p (22).
Our primary ﬁnding on chromosome 19q is novel and
does not overlap with any regions reported by other
authors. In contrast, our secondary ﬁnding on chromo-
some 2q overlaps exactly with a recently reported linkage
result from the Family Investigation of Nephropathy and
Diabetes (FIND) study for UAE variation in several ethic
groups (23). The region from FIND spanned markers
D2S410–D2S1328 located at 127–138 cM. Among our ter-
tiary results, chromosome 1q is novel, while there is some
agreement with the results on chromosome 20p and 3q.
Speciﬁcally, our ﬁnding on chromosome 20p seems to
validate a ﬁnding reported in a genome scan of 59 Pima
Indian families with 98 sibpairs concordant for both type 2
diabetes and diabetic nephropathy (21). An MLS  1.8 was
found near D20S115 (24.7 cM) and a two-point MLS  1.9
was found near GATA65E01 (57.2 cM). Speaking broadly,
the location of our tertiary peak on 3q is in agreement with
seven previous studies (Table 4). However, the location of
peaks varied between 95 and 210 cM. In our current study,
we found two minor peaks 58 cM apart.
Phenotypic or genetic heterogeneity may underlie these
discrepant results. For example, in our pilot study, we had
66 DSPs and we found a peak with MLS  3.1 on
chromosome 3q, close to our current ESRD peak (MLS 
1.1). The current study comprised 48 original and 52 new
DSPs. In the 48 DSPs, the MLS was 2.6 at 154 cM. In the
new 52 DSPs, we identiﬁed only modest evidence for
linkage (MLS  1.3) at position 103 cM. The noticeable
difference between the groups was signiﬁcantly shorter
diabetes duration in diabetic nephropathy cases in the
original DSPs. Due to the small number of DSPs, it is
impossible to evaluate whether this phenotypic difference
could explain the different linkage results. In our previous
publication, however, we demonstrated an effect of diabe-
tes duration at onset of complications on the results of
genetic studies (27).
There are certain limitations to this study. First, DSP
studies are prone to inﬂated MLS values if allele-sharing
patterns are improperly estimated (e.g., due to missing
parents). In our study, in 26 families, neither parent was
genotyped. We attempted to minimize any bias by choos-
ing a highly reliable genotyping platform and being diligent
in removing markers failing to meet strict quality-control
standards. Our conﬁdence in the genotyping platform is
based on previous validation as well as nearly 30,000
replicate quality-control genotypes from ﬁve samples in
our study. As a further check, we reanalyzed the top peaks
using subsets of every third marker and found consistency
in each of the three subsets (data not shown). Such
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genotyping errors. Inclusion of diabetic nephropathy ASPs
would have been another way to mitigate the risk of
misgenotyping, and methods to analyze DSPs and ASPs
together exist (28,29). However, as documented (7), col-
lection of diabetic nephropathy ASPs is extremely difﬁcult
and, being concordant for both diabetic nephropathy and
type 1 diabetes, these siblings would present an additional
challenge in terms of interpretation. Second, while 100
DSPs are sufﬁcient to detect a major locus, the power to
detect moderate/minor genetic players is more modest.
Moreover, the subanalyses we performed by distinguish-
ing ESRD from proteinuria was a post hoc analysis that
should be viewed as exploratory. Third, mortality in ESRD
is quite high (30), leading, potentially, to survival bias. This
could manifest through reduced power among the 50
ESRD DSPs, which might be misinterpreted as phenotypic
heterogeneity, or through drop-out of poor survivors with
ESRD such that the genetic variants associated with good
survival would appear to be related to diabetic nephropa-
thy susceptibility. Fourth, while two loci (DSP triangle
MLS  3.1 on chromosome 19 and ASP triangle MLS  3.1
on chromosome 6q) were “suggestive” (17), none except
HLA achieved “signiﬁcance” (triangle MLS 4.0). There-
fore, our results must be considered largely as hypothesis
generating. Given the difﬁculty in assembling collections
of sibs concordant for type 1 diabetes and discordant for
diabetic nephropathy, a more practical approach may be
to now focus on detecting association using resources
such as GoKinD (31).
In conclusion, our study has provided two sets of genome
scan results: one for type 1 diabetes using 130 ASPs and
another for diabetic nephropathy using 100 DSPs. The type 1
diabetes scan overwhelmingly conﬁrmed the HLA region on
chromosome 6p and it provided additional support for
IDDM15. The diabetic nephropathy scan introduced a new
candidate region on chromosome 19q and conﬁrmed linkage
to UAE on chromosome 2q reported by the FIND study.
Using exploratory subset analysis based on the degree of
diabetic nephropathy, we found a novel locus on chromo-
some 1q and conﬁrmed a locus on chromosome 20p de-
scribed in Pima Indians. Finally, we found evidence for two
loci on chromosome 3q, adding to the list of positive studies
on this chromosome. Taken together, the results from our
diabetic nephropathy scan suggest several loci as candidates
for susceptibility, none of which appear to the sole determi-
nant of diabetic nephropathy.
ACKNOWLEDGMENTS
This research has been supported by National Institutes of
Health Grants DK 053534 and DK 077532. K.W. has been
supported by Juvenile Diabetes Research Federation Fel-
lowship no. 3-2005-908.
All supplemental tables and ﬁgures can be obtained online at
http://www.joslinresearch.org/LabSites/Krolewski/t1dn.dsp/.
REFERENCES
1. Parving HH, Mauer M, Ritz E: Diabetic nephropathy. In Brenner and
Rector’s The Kidney. 7th ed. Brenner BM, Ed. Philadelphia, Elsevier, 2004,
p. 1777–1818
2. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic
kidney disease: evidence for genetic susceptibility to diabetic nephropa-
thy. N Engl J Med 320:1161–1165, 1989
3. Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS,
Deckert T, Parving HH: Is diabetic nephropathy and inherited complica-
tion? Kidney Int 41:719–722, 1992
4. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors
determine the development of diabetic nephropathy in patients with
IDDM. Diabetologia 39:940–945, 1996
5. The Diabetes Control and Complications Trial Research Group: Clustering
TABLE 4
Summary of linkage results reported on chromosome 3q
Authors Study design Phenotype MLS Markers Genetic position*
Studies in type 1
diabetes
Moczulski et al. (8)
(Caucasians)
DSP (n  66) Proteinuria and ESRD 3.1 D3S1308 157.0
Osterholm et al. (20)
(Caucasians)
DSP (n  83) Proteinuria 2.7 D3S3606–
D3S3694
134.6–148.8
Current study
(Caucasians)
DSP (n  50)
DSP (n  50)
Proteinuria
ESRD
1.5
1.1
rs1002200
rs1381768
95.6
154.2
Studies in type 2
diabetes
Imperatore et al. (24)
(Pima Indians)
ASP (n  90) Proteinuria and ESRD 1.5 D3S3053 174
Bowden et al. (25)
(African
Americans)
ASP (n  206) ESRD 1.3 (4.6)† D3S2460 126
Krolewski et al. (21)
Caucasians)
Quantitative trait
loci using 5,656
relative pairs
UAE 1.0 D3S1744 153.4
Placha et al. (22)
(Caucasians)
Quantitative trait loci
using 5,187 relative
pairs
GFR estimated by
cystatin C
(nondiabetic
relative pairs only)
2.8 D3S1744 153.4
Chen et al. (26)
(West Africans)
Quantitative trait loci
using 360 relative
pairs
Serum creatinine 2.2 D3S2418 210
*cM according to the deCODE map. †Ordered subset analysis.
J.J. ROGUS AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 2525of long-term complications in families with diabetes in the Diabetes
Control and Complications Trial. Diabetes 46:1829–1839, 1997
6. Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J: Population-based
assessment of familial clustering of diabetic nephropathy in type 1
diabetes. Diabetes 53:2449–2454, 2004
7. Rogus JJ, Krolewski AS: Using discordant sib pairs to map loci for
qualitative traits with high sibling recurrence risk. Am J Hum Genet
59:1376–1381, 1996
8. Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS: Major
susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q:
results of novel discordant sibpair analysis. Diabetes 47:1164–1169, 1998
9. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of IDDM
on the prevalence of stages of diabetic nephropathy deﬁned by urinary
albumin/creatinine ratio. J Am Soc Nephrol 7:930–937, 1996
10. McPeek S: Statistical tests for detection of misspeciﬁed relationships by
use of genome-screen data. Am J Hum Genet 66:1076–1094, 2000
11. O’Connell JR, Weeks DE: PedCheck: a program for identifying genotype
incompatibilities in linkage analysis. Am J Hum Genet 63:259–266, 1998
12. Abecasis GR, Cherny SS, Cookson WO, Cardon LR: Merlin-rapid analysis of
dense genetic maps using sparse gene ﬂow trees. Nat Genet 30:97–101, 2002
13. Huang Q, Shete S, Amos CI: Ignoring linkage disequilibrium among tightly
linked markers induces false-positive evidence of linkage for affected sib
pair analysis. Am J Hum Genet 75:1106–1112, 2004
14. Abecasis GR, Wigginton JE: Handling marker-marker linkage disequilibrium:
pedigree analysis with clustered markers. Am J Hum Genet 77:754–767, 2005
15. Boyles AL, Scott WK, Martin ER, Schmidt S, Li YJ, Ashley-Koch A, Bass
MP, Schmidt M, Pericak-Vance MA, Speer MC, Hauser ER: Linkage
disequilibrium inﬂates type I error rates in multipoint linkage analysis
when parental genotypes are missing. Hum Hered 59:220–227, 2005
16. Poznik GD, Adamska K, Xu X, Krolewski AS, Rogus JJ: A novel framework
for sib pair linkage analysis. Am J Hum Genet 78:222–230, 2006
17. Lander E, Kruglyak L: Genetic dissection of complex traits: guidelines for
interpreting and reporting linkage results. Nat Genet 11:241–247, 1995
18. Lunetta KL, Rogus JJ: Strategy for mapping minor histocompatibility genes
involved in graft-versus-host disease: a novel application of discordant sib
pair methodology. Genet Epidemiol 15:595–607, 1998
19. Holmans P: Asymptotic properties of affected-sib-pair linkage analysis.
Am J Hum Genet 52:362–374, 1993
20. Osterholm AM, He B, Pitkaniemi J, Albinsson L, Berg T, Sarti C, Tuom-
ilehto J, Tryggvason K: Genome-wide scan for type 1 diabetic nephropathy
in the Finnish population reveals suggestive linkage to a single locus on
chromosome 3q. Kidney Int 71:140–145, 2007
21. Krolewski AS, Poznik DG, Placha GP, Canani L, Dunn J, Walker W, Smiles
A, Krolewski B, Fogarty D, Moczulski D, Araki S, Makita Y, Ng DPK, Rogus
JJ, Duggirala R, Rich SS, Warram JH: A genome-wide linkage scan for
genes controlling variation in urinary albumin excretion in type 2 diabetes.
Kidney Int 69:129–136, 2006
22. Placha G, Poznik GD, Dunn J, Smiles A, Krolewski B, Glew T, Puppala S,
Schneider J, Rogus JJ, Rich SS, Duggirala R, Warram JH, Krolewski AS: A
genome-wide linkage scan for genes controlling variation in renal function
estimated by serum cystatin C levels in extended families with type 2
diabetes. Diabetes 55:3358–3365, 2006
23. Iyengar SK, Abboud He, Goddard KA, Saad MF, Adler SG, Arar NH,
Bowden DW, Duggirala R, Elston RC, Hanson RL, Ipp E, Kao WH, Kimmel
PL, Klag MJ, Knowler WC, Meoni LA, Nelson RG, Nicholas SB, Pahl MV,
Parekh RS, Quade SR, Rich SS, Rotter JI, Scavini M, Schelling JR, Sedor JR,
Sehgal AR, Shah VO, Smith MW, Taylor KD, Winkler CA, Zager PG,
Freedman BI: Genome-wide scans for diabetic nephropathy and albumin-
uria in multiethnic populations: the Family Investigation of Nephropathy
and Diabetes (FIND). Diabetes 56:1577–1585, 2007
24. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC:
Sib-pair linkage analysis for susceptibility genes for microvascular complica-
tions among Pima Indians with type 2 diabetes: Pima Diabetes Genes Group.
Diabetes 47:821–830, 1998
25. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson
PJ, Rich SS, Freedman BI: A genome scan for diabetic nephropathy in
African Americans. Kidney Int 66:1517–1526, 2004
26. Chen G, Adeyemo AA, Zhou J, Chen Y, Doumatey A, Lashley K, Huang H,
Amoah A, Agyenim-Boateng K, Eghan BA, Okafor G, Acheampong J, Oli J,
Fasanmade O, Johnson T, Rotimi C: A genome-wide search for linkage to
renal function phenotypes in West Africans with type 2 diabetes. Am J
Kidney Dis 49:394–400, 2007
27. Rogus JJ, Warram JH, Krolewski AS: Genetics studies of late diabetic
complications: the overlooked importance of diabetes duration before
complication onset. Diabetes 51:1655–1662, 2002
28. Shih PY, Wang T, Xing C, Sinha M, Song Y, Elston RC: Linkage analysis of
alcohol dependence using both affected and discordant sib pairs. BMC
Genet 6 (Suppl. 1):S36, 2005
29. Xing C, Sinha R, Xing G, Lu Q, Elston RC: The affected-/discordant-sib-pair
design can guarantee validity of multipoint model-free linkage analysis of
incomplete pedigrees when there is marker-marker disequilibrium. Am J
Hum Genet 79:396–401, 2006
30. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR:
Development and progression of nephropathy in type 2 diabetes: the
United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int
63:225–232, 2003
31. Mueller PM, Rogus JJ, Cleary PA, Zhao Y, Smiles AM, Steffes MW, Bucksa
J, Gibson TB, Cordovado SK, Krolewski AS, Nierras CR, Warram JH: The
Genetics of Kidneys in Diabetes (GoKinD) Study: a genetics collection
available for identifying the genetic susceptibility factors for diabetic
nephropathy in type 1 diabetes mellitus. J Am Soc Neph 17:1782–1790, 2006
SUSCEPTIBILITY GENES FOR DIABETIC NEPHROPATHY
2526 DIABETES, VOL. 57, SEPTEMBER 2008